癌症表观遗传学、肿瘤免疫与免疫治疗。
Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
机构信息
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA; Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, USA.
Department of Pathology, Yale Cancer Center, Yale Stem Cell Center, Yale School of Medicine, New Haven, CT 06520, USA.
出版信息
Trends Cancer. 2020 Jul;6(7):580-592. doi: 10.1016/j.trecan.2020.02.003. Epub 2020 Mar 31.
Abstract
Epigenetic mechanisms, including DNA methylation, histone post-translational modifications, and chromatin structure regulation, are critical for the interactions between tumor and immune cells. Emerging evidence shows that tumors commonly hijack various epigenetic mechanisms to escape immune restriction. As a result, the pharmaceutical modulation of epigenetic regulators, including 'writers', 'readers', 'erasers', and 'remodelers', is able to normalize the impaired immunosurveillance and/or trigger antitumor immune responses. Thus, epigenetic targeting agents are attractive immunomodulatory drugs and will have major impacts on immuno-oncology. Here, we discuss epigenetic regulators of the cancer-immunity cycle and current advances in developing epigenetic therapies to boost anticancer immune responses, either alone or in combination with current immunotherapies.
摘要
表观遗传机制，包括 DNA 甲基化、组蛋白翻译后修饰和染色质结构调控，对于肿瘤细胞和免疫细胞之间的相互作用至关重要。新出现的证据表明，肿瘤通常会利用各种表观遗传机制来逃避免疫限制。因此，对表观遗传调节剂（包括“写入器”、“读取器”、“擦除器”和“重塑器”）的药物调节能够使受损的免疫监视正常化和/或触发抗肿瘤免疫反应。因此，表观遗传靶向药物是有吸引力的免疫调节药物，将对肿瘤免疫治疗产生重大影响。在这里，我们讨论了癌症-免疫循环的表观遗传调节剂以及目前开发表观遗传疗法的进展，这些疗法可以单独或与现有的免疫疗法联合增强抗肿瘤免疫反应。
相似文献
1
Cancer Epigenetics, Tumor Immunity, and Immunotherapy.癌症表观遗传学、肿瘤免疫与免疫治疗。
Trends Cancer. 2020 Jul;6(7):580-592. doi: 10.1016/j.trecan.2020.02.003. Epub 2020 Mar 31.
2
Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.表观遗传修饰剂：具有免疫调节潜力的抗肿瘤药物。
Front Immunol. 2021 Mar 30;12:652160. doi: 10.3389/fimmu.2021.652160. eCollection 2021.
3
Epigenetics and immunotherapy: The current state of play.表观遗传学与免疫疗法：当前进展情况
Mol Immunol. 2017 Jul;87:227-239. doi: 10.1016/j.molimm.2017.04.012. Epub 2017 May 14.
4
Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment.癌症中的抗病毒反应：通过激活肿瘤微环境中的干扰素通路增强抗肿瘤免疫。
Front Immunol. 2021 Dec 2;12:782852. doi: 10.3389/fimmu.2021.782852. eCollection 2021.
5
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.表观遗传调控抗肿瘤免疫以改善癌症免疫治疗。
Mol Cancer. 2021 Dec 20;20(1):171. doi: 10.1186/s12943-021-01464-x.
6
Epigenetics meets immune checkpoints.表观遗传学与免疫检查点相遇。
Semin Oncol. 2015 Jun;42(3):506-13. doi: 10.1053/j.seminoncol.2015.02.003. Epub 2015 Feb 14.
7
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.表观遗传药物作为癌症治疗中的多效性药物：生物分子方面及临床应用
J Cell Physiol. 2007 Aug;212(2):330-44. doi: 10.1002/jcp.21066.
8
Epigenetic Regulation of Inflammatory Responses in the Context of Physical Activity.运动背景下炎症反应的表观遗传调控。
Genes (Basel). 2021 Aug 25;12(9):1313. doi: 10.3390/genes12091313.
9
Surmounting cancer drug resistance: New insights from the perspective of N-methyladenosine RNA modification.克服癌症药物耐药性：N6-甲基腺苷 RNA 修饰视角的新见解。
Drug Resist Updat. 2020 Dec;53:100720. doi: 10.1016/j.drup.2020.100720. Epub 2020 Aug 20.
10
Immunometabolism: A 'Hot' Switch for 'Cold' Pediatric Solid Tumors.免疫代谢：为小儿实体瘤这一“冷肿瘤”按下“热键”。
Trends Cancer. 2021 Aug;7(8):751-777. doi: 10.1016/j.trecan.2021.05.002. Epub 2021 Jun 26.
引用本文的文献
1
Role of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives.免疫疗法在卵巢癌中的作用：进展、挑战及未来展望
Cancer Treat Res. 2025;129:187-220. doi: 10.1007/978-3-031-97242-3_10.
2
RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications.癌症中的RNA表观遗传学：当前认知与治疗意义
MedComm (2020). 2025 Aug 3;6(8):e70322. doi: 10.1002/mco2.70322. eCollection 2025 Aug.
3
Mitophagy's impacts on cancer and neurodegenerative diseases: implications for future therapies.线粒体自噬对癌症和神经退行性疾病的影响：对未来治疗的启示
J Hematol Oncol. 2025 Aug 1;18(1):78. doi: 10.1186/s13045-025-01727-w.
4
Necroptosis in cancer: insight from epigenetic, post-transcriptional and post-translational modifications.癌症中的坏死性凋亡：来自表观遗传、转录后和翻译后修饰的见解
J Hematol Oncol. 2025 Jul 30;18(1):77. doi: 10.1186/s13045-025-01726-x.
5
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.癌症中的免疫逃逸：机制与前沿治疗方法。
Signal Transduct Target Ther. 2025 Jul 31;10(1):227. doi: 10.1038/s41392-025-02280-1.
6
Unveiling Epigenetic Regulatory Elements Associated with Breast Cancer Development.揭示与乳腺癌发展相关的表观遗传调控元件。
Int J Mol Sci. 2025 Jul 8;26(14):6558. doi: 10.3390/ijms26146558.
7
Stemness signatures reflect prognostic disturbances in gastric cancer.干性特征反映了胃癌中的预后紊乱。
World J Gastrointest Oncol. 2025 Jul 15;17(7):107211. doi: 10.4251/wjgo.v17.i7.107211.
8
The dark matter in cancer immunology: beyond the visible- unveiling multiomics pathways to breakthrough therapies.癌症免疫学中的暗物质：超越可见——揭示通向突破性疗法的多组学途径。
J Transl Med. 2025 Jul 22;23(1):808. doi: 10.1186/s12967-025-06839-y.
9
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.将表观遗传调节因子作为克服癌症治疗耐药性的一条有前景的途径。
Signal Transduct Target Ther. 2025 Jul 18;10(1):219. doi: 10.1038/s41392-025-02266-z.
10
Applications of CRISPR-Cas9 in mitigating cellular senescence and age-related disease progression.CRISPR-Cas9在减轻细胞衰老和与年龄相关疾病进展方面的应用。
Clin Exp Med. 2025 Jul 8;25(1):237. doi: 10.1007/s10238-025-01771-3.
本文引用的文献
1
First EZH2 Inhibitor Approved-for Rare Sarcoma.首款EZH2抑制剂获批用于罕见肉瘤。
Cancer Discov. 2020 Mar;10(3):333-334. doi: 10.1158/2159-8290.CD-NB2020-006. Epub 2020 Feb 10.
2
Advances in epigenetics link genetics to the environment and disease.表观遗传学的进展将遗传学与环境和疾病联系起来。
Nature. 2019 Jul;571(7766):489-499. doi: 10.1038/s41586-019-1411-0. Epub 2019 Jul 24.
3
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer.HDAC6 抑制与抗 PD-L1 治疗联合应用于 ARID1A 失活的卵巢癌。
Cancer Res. 2019 Nov 1;79(21):5482-5489. doi: 10.1158/0008-5472.CAN-19-1302. Epub 2019 Jul 16.
4
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.劫持抗体诱导的 CTLA-4 溶酶体降解以实现更安全、更有效的癌症免疫治疗。
Cell Res. 2019 Aug;29(8):609-627. doi: 10.1038/s41422-019-0184-1. Epub 2019 Jul 2.
5
Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer.赖氨酸特异性组蛋白去甲基化酶 1A 调控三阴性乳腺癌肿瘤微环境中的巨噬细胞极化和检查点分子。
Front Immunol. 2019 Jun 12;10:1351. doi: 10.3389/fimmu.2019.01351. eCollection 2019.
6
Chromatin Architecture as an Essential Determinant of Dendritic Cell Function.染色质结构作为树突状细胞功能的重要决定因素。
Front Immunol. 2019 Jun 4;10:1119. doi: 10.3389/fimmu.2019.01119. eCollection 2019.
7
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.评估有资格接受和对检查点抑制剂免疫治疗药物有反应的美国癌症患者的百分比。
JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535.
8
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.选择性 HDAC6 抑制剂通过减少肿瘤细胞中巨噬细胞的抗炎表型和抑制性免疫蛋白的下调，改善抗 PD-1 免疫检查点阻断治疗。
Sci Rep. 2019 Apr 16;9(1):6136. doi: 10.1038/s41598-019-42237-3.
9
PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targeted p185 Tumor Immunotherapy.PRMT5 与 FOXP3 同源二聚体结合，当被抑制时可增强靶向 p185 肿瘤免疫治疗。
Front Immunol. 2019 Feb 8;10:174. doi: 10.3389/fimmu.2019.00174. eCollection 2019.
10
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.树突状细胞与肿瘤微环境中的 CD8 T 细胞免疫
Front Immunol. 2018 Dec 20;9:3059. doi: 10.3389/fimmu.2018.03059. eCollection 2018.
Zotero 插件